Alasdair J Coles

List of Publications by Year
in descending order

108	17,068	46918 47	29081 104
papers	citations	h-index	g-index

112	112	112	14587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multiple sclerosis. Lancet, The, 2008, 372, 1502-1517.	6.3	3,988
2	Multiple sclerosis. Lancet, The, 2002, 359, 1221-1231.	6.3	1,792
3	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	6.3	1,041
4	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	6.3	1,040
5	Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. New England Journal of Medicine, 2008, 359, 1786-1801.	13.9	927
6	Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology, 1999, 46, 296-304.	2.8	494
7	The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology, 2006, 253, 98-108.	1.8	469
8	Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet, The, 1999, 354, 1691-1695.	6.3	447
9	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
10	Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology, 2005, 35, 3332-3342.	1.6	279
11	Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology, 2011, 258, 686-688.	1.8	277
12	Mutations in the selenocysteine insertion sequenceâ€“binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. Journal of Clinical Investigation, 2010, 120, 4220-4235.	3.9	268
13	IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Journal of Clinical Investigation, 2009, 119, 2052-61.	3.9	257
14	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain, 1996, 119, 225-237.	3.7	249
15	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.5	232
16	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
17	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 208-215.	0.9	208
18	B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis. Journal of Clinical Immunology, 2010, 30, 99-105.	2.0	207

#	Article	IF	Citations
19	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.5	188
20	Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20200-20205.	3.3	185
21	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain, 2013, 136, 2888-2903.	3.7	174
22	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 298-304.	0.9	171
23	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	0.5	169
24	Neurological Implications of COVID-19 Infections. Neurocritical Care, 2020, 32, 667-671.	1.2	165
25	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain, 2010, 133, 2232-2247.	3.7	152
26	Quantifying normal human brain metabolism using hyperpolarized [1â€“13C]pyruvate and magnetic resonance imaging. NeuroImage, 2019, 189, 171-179.	2.1	144
27	Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet, The, 2021, 398, 1147-1156.	6.3	141
28	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
29	Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology, The, 2011, 10, 338-348.	4.9	125
30	Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology, 2013, 81, 872-876.	1.5	120
31	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	0.9	97
32	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood, 2011, 118, 6299-6305.	0.6	96
33	Antibody-mediated encephalitis: a treatable cause of schizophrenia. British Journal of Psychiatry, 2012, 200, 92-94.	1.7	94
34	Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clinical Neurology and Neurosurgery, 2004, 106, 270-274.	0.6	90
35	Promoting remyelination in multiple sclerosis. Journal of Neurology, 2021, 268, 30-44.	1.8	79
36	Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. European Journal of Neuroscience, 2003, 18, 2527-2537.	1.2	73

#	Article	IF	Citations
37	A Novel Strategy To Reduce the Immunogenicity of Biological Therapies. Journal of Immunology, 2010, 185, 763-768.	0.4	65
38	Alemtuzumab Therapy for Multiple Sclerosis. Neurotherapeutics, 2013, 10, 29-33.	2.1	63
39	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	1.5	63
40	Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series. Schizophrenia Research, 2014, 160, 193-195.	1.1	62
41	Guidelines on the use of irradiated blood components. British Journal of Haematology, 2020, 191, 704-724.	1.2	61
42	Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3010-3018.	1.8	57
43	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	1.4	57
44	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.5	55
45	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology, 2014, 82, 2158-2164.	1.5	52
46	Mode of action and clinical studies with alemtuzumab. Experimental Neurology, 2014, 262, 37-43.	2.0	51
47	Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open, 2018, 8, e025333.	0.8	51
48	Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) Tâ€„cells. European Journal of Immunology, 2005, 35, 3694-3703.	1.6	50
49	Hyperpolarized ¹³C MRI: A novel approach for probing cerebral metabolism in health and neurological disease. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1137-1147.	2.4	49
50	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight, 2017, 2, .	2.3	46
51	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, The, 2021, 20, 709-720.	4.9	44
52	Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 795-798.	0.9	42
53	Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Multiple Sclerosis and Related Disorders, 2022, 57, 103458.	0.9	40
54	New treatment strategies in multiple sclerosis. Experimental Neurology, 2010, 225, 34-39.	2.0	39

#	Article	IF	Citations
55	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Journal of Neurology, 2016, 263, 25-29.	1.8	39
56	Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain, 2018, 141, 786-796.	3.7	39
57	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 107-109.	0.9	38
58	Antiâ€Lâ€7 receptor Î± monoclonal antibody (GSK2618960) in healthy subjects â€“ a randomized, doubleâ€blind, placeboâ€controlled study. British Journal of Clinical Pharmacology, 2019, 85, 304-315.	1.1	36
59	Campath-1H Treatment of Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 27-31.	0.8	34
60	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 52, 102939.	0.9	34
61	'Radiologically compatible CLIPPERS' may conceal a number of pathologies. Brain, 2011, 134, e187-e187.	3.7	33
62	Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Multiple Sclerosis Journal, 2013, 19, 241-244.	1.4	33
63	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsingâ€remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 60-63.	0.9	32
64	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology, 2018, 90, 849-851.	1.5	32
65	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	0.8	31
66	Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. Journal of Neuroimmunology, 2014, 271, 66-68.	1.1	30
67	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology, 2017, 88, 1004-1006.	1.5	30
68	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	1.5	30
69	Alemtuzumab Treatment of Multiple Sclerosis. Seminars in Neurology, 2013, 33, 066-073.	0.5	29
70	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1273-1288.	1.4	29
71	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. Neurology, 2016, 87, 1464-1472.	1.5	28
72	Multiple sclerosis: THE BARE ESSENTIALS. Practical Neurology, 2009, 9, 118-126.	0.5	27

#	Article	IF	Citations
73	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. Journal of Neurology, 2013, 260, 462-469.	1.8	27
74	Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis. Drug Design, Development and Therapy, 2013, 7, 131.	2.0	26
75	Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1779-1782.	1.4	25
76	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	3.7	24
77	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.4	24
78	Alemtuzumab as Treatment for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032029.	2.9	22
79	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	1.4	21
80	Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 365-367.	0.9	19
81	Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Therapeutic Advances in Neurological Disorders, 2009, 2, 195-203.	1.5	17
82	Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 237-243.	0.9	17
83	Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
84	Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight, 2019, 4, .	2.3	16
85	The impact of smoking cessation on multiple sclerosis disease progression. Brain, 2022, 145, 1368-1378.	3.7	16
86	Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. Journal of the Neurological Sciences, 2016, 363, 188-194.	0.3	15
87	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 295-302.	0.9	15
88	Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Therapeutic Advances in Chronic Disease, 2013, 4, 97-103.	1.1	13
89	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	1.4	13
90	Newer therapies for multiple sclerosis. Annals of Indian Academy of Neurology, 2015, 18, 30.	0.2	11

#	Article	IF	Citations
91	Remyelination in humans due to a retinoidâ€X receptor agonist is ageâ€dependent. Annals of Clinical and Translational Neurology, 2022, 9, 1090-1094.	1.7	10
92	Product licences for alemtuzumab and multiple sclerosis. Lancet, The, 2014, 383, 867-868.	6.3	8
93	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). Trials, 2019, 20, 331.	0.7	7
94	The Outlook for Alemtuzumab in Multiple Sclerosis. BioDrugs, 2013, 27, 181-189.	2.2	6
95	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. Multiple Sclerosis Journal, 2020, 26, 1093-1101.	1.4	6
96	A case of anaphylaxis to alemtuzumab. Journal of Neurology, 2019, 266, 780-781.	1.8	6
97	Physician-assisted death should be available to people with MS â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 1681-1681.	1.4	5
98	Hypothyroid ataxia complicating monoclonal antibody therapy. Practical Neurology, 2017, 17, 482-484.	0.5	4
99	A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers. Journal of Neuroimmunology, 2017, 312, 4-7.	1.1	2
100	Alemtuzumab in Multiple Sclerosis. Noropsikiyatri Arsivi, 2011, 48, 79-82.	0.7	1
101	Progressive multifocal leucoencephalopathy with BehÃ§etâ€™s disease: an insight into pathophysiology. Rheumatology, 2017, 56, kew404.	0.9	1
102	Susacâ€™s syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution. Journal of Neurology, 2022, 269, 1695-1697.	1.8	1
103	Campath, clones and the cause of autoimmunity. Brain, 2022, 145, 1579-1580.	3.7	1
104	Alemtuzumab for the treatment of multiple sclerosis. Future Neurology, 2010, 5, 177-188.	0.9	0
105	Alemtuzumab to treat multiple sclerosis. , 0, , 393-398.		0
106	We are about to cure MS in the next 10 years, even though we do not know its cause: No. Multiple Sclerosis Journal, 2012, 18, 784-785.	1.4	0
107	Targeting CD52 for the Treatment of Multiple Sclerosis. , 2013, , 385-399.		0
108	All manner of ingenuity and industry. Brain, 0, , .	3.7	0